BCR

Breakpoint cluster region protein

123,904 patent compounds predicted against BCR, 86,280 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9469	0.76	18/20
SCHEMBL1365	1.00	17/20
SCHEMBL1255	0.80	17/20
SCHEMBL1430	1.00	16/20
SCHEMBL1442	1.00	16/20
SCHEMBL1465	1.00	16/20
SCHEMBL9338	1.00	16/20
SCHEMBL9485	1.00	16/20
SCHEMBL9565	1.00	16/20
SCHEMBL9763	1.00	16/20
SCHEMBL10208	0.82	16/20
SCHEMBL9862	0.79	16/20
SCHEMBL1762	0.74	16/20
SCHEMBL1522	1.00	15/20
SCHEMBL9642	1.00	15/20
SCHEMBL9838	1.00	15/20
Imatinib (SCHEMBL3827)	1.00	14/20
Imatinib (SCHEMBL8217)	1.00	14/20
SCHEMBL9197	1.00	14/20
SCHEMBL9588	0.98	14/20

Germline variants in BCR on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BCR gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BCR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation	PHASE4	COMPLETED
Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia	PHASE2/PHASE3	COMPLETED
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia	PHASE3	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)	PHASE2	COMPLETED
Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia	PHASE2	UNKNOWN
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML	PHASE1/PHASE2	COMPLETED
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response	PHASE2	COMPLETED
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib	PHASE2	RECRUITING
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy	PHASE2	COMPLETED
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)	PHASE2	NOT_YET_RECRUITING
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia	PHASE2	UNKNOWN
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)	PHASE1	NOT_YET_RECRUITING
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia	PHASE1	COMPLETED
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study	nan	COMPLETED
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log	nan	UNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia	nan	RECRUITING
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment	nan	COMPLETED
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm	nan	UNKNOWN
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Effect of 2nd Gen TKI in CML	nan	COMPLETED
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults	nan	RECRUITING
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia	nan	COMPLETED
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia	nan	UNKNOWN
Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes	nan	UNKNOWN
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	nan	COMPLETED
Allogeneic SCT for CML, TKI Failure After TKI Failure	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a BCR binder may also engage these)

Protein	Name	Similarity
F1LXF1	—	1.000	F1LXF1 →
Q6PAJ1	—	1.000	Q6PAJ1 →
P49797	—	0.985	P49797 →
Q8WXG6	—	0.984	Q8WXG6 →
Q80U28	—	0.984	Q80U28 →
Q92625	—	0.983	Q92625 →
Q66H91	—	0.983	Q66H91 →
CBL	E3 ubiquitin-protein ligase CBL	0.982	landscape →
Q6ZWB6	—	0.982	Q6ZWB6 →
Q66T02	—	0.982	Q66T02 →
Q9Z1N9	—	0.982	Q9Z1N9 →
P22682	—	0.982	P22682 →
Q9BSQ5	—	0.982	Q9BSQ5 →
Q6DRP4	—	0.982	Q6DRP4 →
P0C6S7	—	0.982	P0C6S7 →
Q9UPW8	—	0.982	Q9UPW8 →
Q50H33	—	0.981	Q50H33 →
Q92622	—	0.981	Q92622 →
Q7Z628	—	0.981	Q7Z628 →
Q9UPU7	—	0.981	Q9UPU7 →
Q8BWW9	—	0.981	Q8BWW9 →
Q8K2Y9	—	0.981	Q8K2Y9 →
Q80U40	—	0.981	Q80U40 →
Q8BIZ1	—	0.981	Q8BIZ1 →
P28028	—	0.981	P28028 →
Q69ZK0	—	0.981	Q69ZK0 →
O14795	—	0.981	O14795 →
Q9Z206	—	0.981	Q9Z206 →
Q9Z1T4	—	0.980	Q9Z1T4 →
Q62768	—	0.980	Q62768 →